


Product Information


Description:	Anti-CD19-Anti-CD3-His-Tag is a purified recombinant human bispecific T cell Engager (BiTE®). This molecule has been tested for specific activity in both ELISA binding assay to CD19-biotin and functional reporter assays using Jurkat/NFAT-luc (BPS Bioscience #60621) or Jurkat/IL2-Luc reporter (BPS Bioscience #60481) cell lines in the presence of CD19+ Raji cells.
Concentration:	0.38 mg/ml
Species:	Human
Formulated In:	8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
Expression System:	HEK293
Format:	Aqueous buffer solution
Stability:	At least 12 months at -80°C. Avoid freeze/thaw cycles.
Storage:	-80°C
MW:	54 kDa + glycans
Glycosylation:	This molecule runs at a higher MW by SDS-PAGE due to glycosylation.
Purity:	≥90%
Purification:	Ni-NTA affinity purification of the His-tag protein from HEK293 cells.
Assay Conditions:	Functional activity of anti-CD19-anti-CD3 bispecific molecule was measured using Jurkat effector cells with endogenous TCR/CD3 and transfected reporter NFAT-Luc or IL-2 promoter-Luc and incubated with increasing concentrations of a CD19xCD3 bispecific molecule, in the presence or absence of CD19+ Raji cells. The bispecific molecule (BiTE®) simultaneously then binds to TCR/CD3 on the Jurkat reporter cells and tumor antigen CD19 on the target Raji cells. Finally, the bispecific molecule binding stimulates NFAT or IL-2 luciferase activity.
Applications:	Anti-CD19-Anti-CD3-His-Tag can be used as a reference BiTE® for studying CD19+ cancer cell-mediated T cell activation, using either primary T cells or reporter cell lines such as the NFAT Jurkat Luciferase Cell Line.

Quality Control Data

4-20% SDS-PAGE Coomassie Staining



NFAT Jurkat: Activation of Jurkat Reporter by CD19xCD3 Molecule in Presence of CD19⁺ Raji Cells



IL-2 Jurkat: Activation of Jurkat Reporter by CD19xCD3 Molecule in Presence of CD19⁺ Raji Cells

